Cargando…
A New Compound with Increased Antitumor Activity by Cotargeting MEK and Pim-1
Feedback circuits are one of the major causes underlying tumor resistance. Thus, compounds that target one oncogenic pathway with simultaneously blocking its compensatory pathway will be of great value for cancer treatment. Here, we develop a new MEK inhibitor designated as KZ-02 that exhibits unexp...
Autores principales: | Li, Yanan, Cheng, Ying, Zhang, Maoqi, He, Xiaoli, Kong, Li, Zhou, Kexiang, Zhou, Yunfu, Li, Lin, Tian, Hongqi, Song, Xiaomin, Cui, Yukun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322072/ https://www.ncbi.nlm.nih.gov/pubmed/32585592 http://dx.doi.org/10.1016/j.isci.2020.101254 |
Ejemplares similares
-
Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA
por: Casey, Mika, et al.
Publicado: (2022) -
Cotargeting among microRNAs in the brain
por: Cherone, Jennifer M., et al.
Publicado: (2019) -
Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy
por: Li, Yanan, et al.
Publicado: (2019) -
PICH and Cotargeted Plk1 Coordinately Maintain Prometaphase Chromosome Arm Architecture
por: Kurasawa, Yasuhiro, et al.
Publicado: (2010) -
Current Development Status of MEK Inhibitors
por: Cheng, Ying, et al.
Publicado: (2017)